# Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)

> **NCT03689114** · PHASE4 · COMPLETED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 58 (actual)

## Conditions studied

- Epilepsies, Partial

## Interventions

- **DRUG:** Low dose carbamazepine
- **DRUG:** Standard dose carbamazepine
- **DRUG:** Low dose levetiracetam
- **DRUG:** Standard dose levetiracetam
- **DRUG:** Low dose valproate
- **DRUG:** Standard dose valproate
- **DRUG:** Low dose zonisamide
- **DRUG:** Standard dose zonisamide
- **DRUG:** Low dose oxcarbazepine
- **DRUG:** Standard dose oxcarbazepine
- **DRUG:** Low dose topiramate
- **DRUG:** Standard dose topiramate
- **DRUG:** Low dose lamotrigine
- **DRUG:** Standard dose lamotrigine
- **DRUG:** Low dose gabapentin
- **DRUG:** Standard dose gabapentin

## Key facts

- **NCT ID:** NCT03689114
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-10
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03689114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03689114, "Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03689114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*